Immunotherapy in glioblastoma treatment: Current state and future prospects

World J Clin Oncol. 2023 Apr 24;14(4):138-159. doi: 10.5306/wjco.v14.i4.138.

Abstract

Glioblastoma remains as the most common and aggressive malignant brain tumor, standing with a poor prognosis and treatment prospective. Despite the aggressive standard care, such as surgical resection and chemoradiation, median survival rates are low. In this regard, immunotherapeutic strategies aim to become more attractive for glioblastoma, considering its recent advances and approaches. In this review, we provide an overview of the current status and progress in immunotherapy for glioblastoma, going through the fundamental knowledge on immune targeting to promising strategies, such as Chimeric antigen receptor T-Cell therapy, immune checkpoint inhibitors, cytokine-based treatment, oncolytic virus and vaccine-based techniques. At last, it is discussed innovative methods to overcome diverse challenges, and future perspectives in this area.

Keywords: Brain cancer; Chimeric antigen receptor T cell; Glioblastoma; Immune-checkpoint inhibitors; Immunotherapy; Oncolytic viruses; Tumor microenvironment.

Publication types

  • Review